Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma

• DOI: 10.21037/jgo-22-882
• Publication Date: 2023-05-12T01:26:26Z
• Authors: Hannah M. Lee; Laura Alder; Matthew Nguyen; Sean C. Dougherty; Yuesheng Qu; Leroy R. Thacker; Andrew Poklepovic
• Keywords: Liver Cancer; Liver function

Yttrium-90 (Y90) radioembolization is a catheter-based therapy for hepatocellular carcinoma (HCC). Multiple trials have evaluated the efficacy of Y90 in HCC; however, few assessed long-term hepatic function. This study aimed to evaluate clinical real-world experience effectiveness and impact on function.A single-center retrospective chart review was performed patients with Child-Pugh (CP) class A or B who received primary HCC between 2008 2016. Model end-stage liver disease (MELD) CP scores were calculated day treatment 1, 3, 6, 12, 24 months post-procedure.Of 134 included, mean age 60 years old median overall survival (OS) from date diagnosis 28 [95% confidence interval (CI): 22.21-38.05]. Patients (85%) had progression-free (PFS) 3 (95% CI: 2.99-5.55) OS 17 9.59-23.10) compared PFS 4 2.07-8.28) 8 4.60-15.64) B. MELD significantly higher post-treatment than pre-treatment, significant recovery at months. No differences seen cancer stage OS, while did show difference 1 longer 1.While our supports literature Y90-treated patients, we found shorter this population. may reflect utilization RECIST radiology practice determining progression. Significant factors associated age, MELD, portal vein thrombosis (PVT). For PFS, score significant. Increasing over time likely reflected combination radioembolization-induced disease, decompensation progression HCC. The downtrend due long term survivors benefit no complications Y90.